Articles tagged with Rheumatoid Arthritis
Baricitinib demonstrates dose-dependent efficacy in active rheumatoid arthritis, with 76% of patients achieving ACR20 response compared to 41% on placebo. Patients also showed significant improvements in disease activity and functional outcomes.
A study presented at EULAR 2012 found that biologic treatments significantly reduce mortality risk in rheumatoid arthritis patients. Achieving early and sustained remission is associated with improved overall survival.
A retrospective analysis found that cumulative anti-TNF therapy for 1-3 years reduced cardiovascular event risk by 24-56% in RA patients. Longer treatment duration further decreased risk, particularly among older patients and those without prior methotrexate use.
A study at EULAR 2012 found that tailoring biologic treatment to individual patients with rheumatoid arthritis can save €2,595,557 in costs over three years while increasing effectiveness by an average of 3.67 quality-adjusted life years
A head-to-head study in rheumatoid arthritis patients found that abatacept achieved comparable efficacy to adalimumab, with similar rates of ACR20 and ACR50 responses. The study also showed fewer injection site reactions with abatacept.
A study found that 22% of European countries have no biologics reimbursed for rheumatoid arthritis treatment, with inconsistent criteria across the continent. This leads to unequal access to essential medications, affecting patients' health status and socio-economic welfare.
The ADACTA trial showed that tocilizumab was more effective than adalimumab in reducing signs and symptoms of rheumatoid arthritis (RA), with significant improvements in DAS28, low disease activity, and ACR20/50/70 responses. Safety results were similar between groups.
Researchers used echocardiograms to spot early heart disease in rheumatoid arthritis patients. The study found that the condition is often underestimated by traditional risk assessment tools.
Rheumatoid arthritis patients face a higher risk of early death and cardiovascular disease due to inflammation. Conventional predictors of risk are inadequate for estimating this risk, emphasizing the need for more accurate tools to assess heart disease danger in these patients.
Researchers discovered that the Notch pathway contributes to the development of rheumatoid arthritis by influencing the differentiation and function of inflammatory macrophages. The study also shows that drugs under development for cancer could potentially be used to treat RA.
Researchers discovered that 40% of LGL patients have a STAT3 mutation, which may aid in diagnosing and treating the disease. The mutation is also associated with an increased risk of rheumatoid arthritis, opening new avenues for understanding its pathogenesis.
Researchers at The Wistar Institute found that a diverse array of regulatory T cells is necessary to prevent the immune system from generating tissue-specific inflammation in rheumatoid arthritis. This diversity provides a cumulative protective effect against the disease.
A Mayo Clinic study of 813 adults with rheumatoid arthritis found that obesity accounted for 52% of the increase in cases among women from 1985-2007. The study suggests a potential link between excess weight and autoimmune diseases like rheumatoid arthritis.
A Mayo Clinic study reveals that people with rheumatoid arthritis are at a higher risk of developing lower gastrointestinal issues, which can be life-threatening. Smoking, steroid use, and prior abdominal surgery increase the risk, emphasizing the need for new prevention and treatment strategies.
The American College of Rheumatology (ACR) has endorsed six standardized measures to determine rheumatoid arthritis disease activity. These measures are sensitive to change, can discriminate between low, moderate, and high disease activity states, and include remission criteria, making them feasible to perform in a clinical setting.
The American College of Rheumatology (ACR) has released updated guidelines for the use of disease-modifying antirheumatic drugs (DMARDs) and biologic agents in treating rheumatoid arthritis. The new recommendations aim to improve treatment outcomes and quality of life for patients.
Patients with rheumatoid arthritis who discontinue statin therapy are at increased risk of cardiovascular disease and other causes. A population-based study found that RA patients should be advised to maintain medication compliance to reduce mortality risk.
A new study by Brigham and Women's Hospital researchers has developed a statistical method to estimate the heritable component of four common diseases. The study found that hundreds of loci with common causal variants explain most of the risk for these diseases, not rare mutations.
Researchers have found a new potential target for rheumatoid arthritis by developing an agent that prevents activated T cells from migrating towards the site of inflammation. The agent, PS372424, binds to a specific receptor CXCR3 on activated T cells and 'blinds' them, preventing further damage.
Research published in Arthritis Care & Research found that women with rheumatoid arthritis and lupus tend to have fewer children than desired due to increased infertility rates. The study also revealed that concerns about caring for children and genetic transmission of the disease may contribute to this trend.
A new study found that 2 in 5 adults with rheumatoid arthritis (RA) were inactive, with motivation and beliefs about exercise being key risk factors. Researchers suggest that promoting physical activity can improve RA management and overall public health.
Researchers found that glucocorticoid therapy can decrease citrullination and PAD4 enzyme levels in people with rheumatoid arthritis, leading to reduced inflammation. Treatment had no effect on methotrexate, but showed promising results for RA management.
Researchers found that patients taking anti-TNF medications for rheumatoid arthritis had a higher rate of post-surgical flares, but no significant increase in infections or complications. The study suggests that adjusting medication withdrawal timing based on individual half-lives may minimize disease flares
A new study found that rheumatoid arthritis patients who undergo total knee replacement surgery have lower expectations about their postsurgical outcomes compared to osteoarthritis patients. This can lead to worse outcomes due to reduced motivation for rehabilitation, resulting in decreased function and overall quality of life.
Women under 50 with rheumatoid arthritis are more likely to break bones than their counterparts, according to a Mayo Clinic study. Researchers found that even in younger patients, the condition increases fracture risk, particularly in women.
Two new genetic variants, rs4129267 and rs7130588, linked to increased asthma risk have been discovered. These variants may lead to the development of a new treatment for asthma using drugs currently used to treat rheumatoid arthritis.
Researchers at Northwestern University have discovered a new protein called P21, which acts as a protective barrier against hyperactive immune cells in people with rheumatoid arthritis. By inhibiting the immune cells' destructive rampage, the bouncer molecule halts the disease process, offering a promising new avenue for future therapies.
Patients with rheumatoid arthritis who have higher self-efficacy for physical activity are more likely to achieve their goals. Achieving these goals is associated with reduced arthritis pain and increased health-related quality of life.
A defective gene can contribute to the onset of rheumatoid arthritis by disrupting inflammatory responses, and a new mouse model reveals this connection. Researchers identified A20 as a key player in controlling inflammation, suggesting it may be a target for developing new treatments.
A five-year study found that rheumatoid arthritis patients are at higher risk of cardiovascular disease due to inflammation. Treatment with disease-modifying antirheumatic drugs (DMARDs) reduced the risk, while certain risk factors such as diabetes and high blood pressure predicted new events.
Researchers at Mount Sinai Hospital and University of Toronto identified the PTPN22 gene mutation's impact on immune cells, leading to hyper-immune responses and autoimmune disorders. The study's findings will help develop new diagnostic tests and targeted therapies for rheumatoid arthritis and other autoimmune conditions.
A study of nearly 14,000 patients with rheumatoid arthritis or psoriasis found that certain disease-modifying antirheumatic drugs reduced the risk of developing type 2 diabetes. The findings suggest a possible role for immunosuppression in preventing diabetes among patients with systemic inflammatory disorders.
Researchers found that patients with RA or psoriasis who were treated with TNF inhibitors or hydroxychloroquine had a lower risk of developing diabetes. The study suggests an association between these medications and reduced diabetes risk, but the cause is not yet known.
A study of 98,454 patients found that RA patients were approximately 20% less likely to receive standard MI treatments after a heart attack. This trend remained relatively unchanged over time, highlighting potential undertreatment of cardiovascular disease in these patients.
A recent study found that 91% of clinical trials with financial conflicts of interest reported positive outcomes, compared to 66.7% without FCOIs. Authors receiving consulting fees from industry had the strongest correlation with positive trial results.
A new study by EULAR suggests that using placebo in rheumatoid arthritis (RA) clinical trials can negatively impact patients. The study analyzed current study designs for new therapies and found that patients in the placebo group experienced no change in medication, forcing them to continue with their former ineffective treatment.
Patients with rheumatoid arthritis are two times more likely to develop chronic obstructive pulmonary disease (COPD) compared to healthy controls. The study controlling for risk factors like smoking and obesity found a significant association, suggesting a link between the two conditions
A small study on yoga in rheumatoid arthritis patients showed statistically significant improvements in disease activity scores, while another study demonstrated positive effects on the quality of life for patients with fibromyalgia. Yoga practice has been found to reduce anxiety levels and improve overall well-being.
A study found that RA patients had lower seroprotection rates and seroconversion rates compared to healthy individuals after receiving the H1N1 vaccine. This highlights the need for specific immunization strategies for patients with rheumatoid arthritis in future flu pandemics.
The Vectra DA algorithm provides a robust molecular monitoring system for RA disease activity. Studies show it can predict progressive joint damage and is robust in patients with common comorbid conditions.
A recent study published in Nature Immunology has discovered a novel mechanism by which tumor necrosis factor (TNF) suppresses inflammatory responses. The researchers found that TNF activates the glycogen synthase kinase 3-alpha protein and upregulates the A20 gene, leading to reduced inflammation.
A systematic review found that t'ai chi is effective for fall prevention and improving psychological health, with general health benefits for older people. However, its effectiveness for other conditions such as cancer and rheumatoid arthritis is contradictory.
Researchers at NYU Langone Medical Center created a novel protein molecule derived from progranulin, which may offer alternative treatments for chronic inflammatory diseases like rheumatoid arthritis. The protein has been shown to have a high affinity and specificity for binding to tumor necrosis factor receptors.
A recent trial found the combination of rituximab, a TNF inhibitor, and methotrexate showed a consistent safety profile for rheumatoid arthritis patients. While no new safety concerns were identified, clear efficacy benefits were not observed in this study sample.
A study of 162 RA patients found poor sleep quality correlated with higher depressive symptoms, increased fatigue, and greater functional disability. Addressing sleep problems may have a critical impact on the health and lives of patients with RA.
Researchers redefine remission in rheumatoid arthritis by introducing two new provisional definitions that aim to standardize treatment goals. The new definitions focus on disease activity measures, including tender joint count, swollen joint count, and C-reactive protein levels.
A Stanford researcher's study reveals that many rheumatoid arthritis patients are not receiving recommended disease-modifying antirheumatic drugs (DMARDs) due to high costs and health disparities. The study found that 63% of Medicare-managed care patients received any DMARD treatment, with significant variations by income level, race, ...
A study of over 90,000 Medicare managed care patients with rheumatoid arthritis found significant variations in the receipt of recommended medications. Demographic factors such as age, sex, race, socioeconomic status, and geographic location played a role in determining medication use.
In a phase II trial, fostamatinib disodium, an oral spleen tyrosine kinase inhibitor, failed to demonstrate efficacy in patients with rheumatoid arthritis who had not responded to biologic agents. However, the drug was found to be safe and showed promise in subgroups of patients with elevated C-reactive protein levels.
A recent study found that low socioeconomic status is associated with higher rates of depressive symptoms in RA patients. Researchers analyzed data from 466 patients and found significant disparities in mental health outcomes between those with high and low SES.
Researchers estimate lifetime risk of rheumatoid arthritis for both sexes using data from the Rochester Epidemiology Project. The study finds that 8.4% of women and 5.1% of men will develop an inflammatory autoimmune disease in their lifetime.
Current smokers with early rheumatoid arthritis showed reduced response to treatment with methotrexate and tumor necrosis factor inhibitors. The study found that smoking history did not impact the effectiveness of these therapies.
Research published in Annals of the Rheumatic Diseases found that smoking is a major preventable risk factor for rheumatoid arthritis, accounting for over 35% of ACPA positive cases and one in five cases overall. Heavy smokers are more than 2.5 times as likely to test positive for ACPA.
A large-scale study found that patients with rheumatoid arthritis have a 60% higher risk of heart attack just one year after diagnosis, with the risk increasing rapidly in the first few years. The study emphasizes the importance of monitoring heart risk from the moment RA is diagnosed.
A recent study published in Arthritis & Rheumatism found that early diagnosis and treatment with disease-modifying antirheumatic drugs (DMARDs) can significantly improve outcomes for patients with rheumatoid arthritis. Delayed treatment was associated with increased joint destruction and lower chances of achieving DMARD-free remission.
African Americans who smoke cigarettes have a higher risk of developing rheumatoid arthritis (RA), with heavy smokers at greatest risk. The study found that limiting cumulative smoking exposure to less than 10 pack-years could prevent roughly one in six new cases of RA.
Researchers found that homeopathic consultations can significantly reduce symptoms of rheumatoid arthritis when combined with conventional treatment. The benefits were attributed to the consultation process, not the remedies used.
Researchers have discovered that mesenchymal stem cells from umbilical cord blood can suppress inflammation and attenuate collagen-induced arthritis. The study suggests a new potential therapy for rheumatoid arthritis, which currently has limited long-term drug-free remission options.
The study found significant benefits of Tai Chi for individuals with arthritis, including improved pain, fatigue, stiffness, and sense of well-being. Participants showed moderate improvements in physical function performance measures, such as timed chair stands and gait speed.
A new study suggests that bortezomib, a proteasome inhibitor, reduces disease severity and inflammation in an animal model of inflammatory arthritis. The drug promotes bone healing and displays favorable effects in targeting critical cell populations involved in the development of RA.